Stockwatch: An orphan drug too far
This article was originally published in Scrip
Executive Summary
Often when a company releases an announcement that results in its share price going down, and then it keeps going down, the cause for the sell-off is reasonably obvious. Not so for Synageva BioPharma last week. Its positive Phase III trial announcement in the treatment of lysosomal acid lipase (LAL) deficiency was accompanied by a 14% share price drop before the markets closed for the fourth of July weekend (scripintelligence.com, 02 July 2014).